Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Rulonilimab by Shandong New Time Pharmaceutical for Cervical Cancer: Likelihood of Approval
Rulonilimab is under clinical development by Shandong New Time Pharmaceutical and currently in Phase II for Cervical Cancer. According to...